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Background: As BRCA1/2 testing becomes more routine, questions remain about long-term satisfaction and quality
of life following testing. Previously, we described long term distress and risk management outcomes among
women with BRCA1/2 mutations. This study addresses positive psychological outcomes in BRCA1/2 carriers,
describing decision satisfaction and quality of life in the years following testing.
Methods: We evaluated satisfaction with testing and management decisions among 144 BRCA1/2 carriers. Prior to
genetic testing, we assessed family history, sociodemographics and distress. At a mean of 5.3 years post-testing, we
assessed management decisions, satisfaction with decisions and, among women with cancer, quality of life.
Results: Overall, satisfaction with decision making was high. Women who had risk reducing mastectomy or
oophorectomy were more satisfied with management decisions. Participants who obtained a risk reducing
oophorectomy were more satisfied with their genetic testing decision. Among affected carriers, high pretest anxiety
was associated with poorer quality of life and having had risk reducing mastectomy prior to testing was associated
with better quality of life. The negative impact of pre-test anxiety was diminished among women who had
mastectomies before testing.
Conclusions: BRCA1/2 carriers are satisfied with their testing and risk management decisions and report good
quality of life years after testing. Having risk reducing surgery predicts increased satisfaction and improved quality
of life.
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Decisions about genetic testing and medical management
among women at increased risk for breast and ovarian can-
cer are complex and driven by a combination of medical
recommendations and patients’ value-based preferences.
As BRCA1/2 testing has become routine, increasing num-
bers of women now face these decisions. Women who
carry mutations in the BRCA1 or BRCA2 (BRCA1/2) gene
have a lifetime risk of 40% to 75% of developing breast can-
cer and up to a 40% risk of developing ovarian cancer [1].* Correspondence: schwartm@georgetown.edu
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reproduction in any medium, provided the orTo manage these risks they must choose between in-
creased surveillance and risk reducing surgery. Increased
surveillance may involve annual mammography and MRI
for breast cancer and ultrasonagraphy and CA-125 blood
tests for ovarian cancer. Alternatively, surgical options in-
clude risk reducing mastectomy (RRM) and oophorectomy
(RRO). Current guidelines recommend RRO between the
ages of 35 and 40 or upon completion of childbearing
and that RRM be discussed as an option on a case-by-
case basis [2,3].
Several recent studies document that the majority of
BRCA1/2 mutation carriers opt for RRO, RRM or both
[4-10]. Thus, it is critical to understand long-term patient
satisfaction and quality of life following these surgeries. Al-
though prior studies have indicated that patients typicallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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have prospectively compared BRCA1/2 carriers who did
and did not opt for risk reducing surgery. One study,
using single item assessments of satisfaction, found no
difference in satisfaction associated with risk reducing
mastectomy [12]. Other identified correlates of satisfac-
tion include family history, cancer risk, cancer worry
and age [12,13,16]. Of note, the populations in these
studies were selected based on family history rather
than test result, and thus had variable levels of cancer
risks. As such, it is difficult to separate the possibly con-
founding effect of risk on uptake of risk reducing sur-
gery and on satisfaction post-surgery. In terms of RRO,
Madlinska and colleagues evaluated satisfaction using a
series of single item questions in a large cohort of women
(43% of whom were BRCA1/2 mutation carriers) who had
either undergone RRO or gynecologic screening a mean
of four years following a high risk gynecology visit [17]. In
this study, women who had opted for RRO were more
satisfied than those undergoing regular gynecologic
screening, leading the authors to suggest that oophorec-
tomy may be not only medically advantageous, but also
psychologically advantageous for many of the women in
their study.
Despite the apparent high rates of satisfaction with risk
reducing surgery decisions, it remains unclear if such sur-
gery significantly impacts BRCA1/2 carriers’ long-term
quality of life. A short-term negative impact of surgery on
physical functioning domains of quality of life has been
noted, most likely related to recovery from surgery [18],
but most other studies of high risk women suggest
comparable or higher quality of life scores over time, in
association with RRO and RRM [12,17,19-21]. All of
these studies followed women at varying levels of gen-
etic risk and various time points (12 months-10 years)
following risk assessment and/or surgery. None of these
studies were designed to control for the potential con-
founding effect of women making decisions about both
RRM and RRO.
While some high-risk women opt for surgery very soon
after learning their BRCA1/2 mutation status, others make
these decisions over time [4]. As such, long-term pro-
spective studies are necessary to gain a more complete
understanding of the impact of BRCA1/2 testing and sub-
sequent decision-making. Previous reports, including one
from this cohort, have addressed long term distress out-
comes and found that BRCA1/2 carriers experience dis-
tress related to their genetic status that is significantly
greater, though not clinically significant, compared to
those who do not carry BRCA1/2 mutations [22,23].
Questions remain regarding positive outcomes related to
undergoing testing and the decisions made following test-
ing. This study is the first to prospectively examine long-
term satisfaction and quality of life outcomes in a U.S.cohort of BRCA1/2 carriers with and without a history of
cancer. In this report, we describe decisional satisfaction
over time and long-term quality of life, comparing women
who have made different decisions regarding the manage-
ment of their breast and ovarian cancer risk.
Methods
Ethics statement
This study was approved by the Georgetown University
Institutional Review Board (Protocol #2003-004, “Long
Term Outcomes of BRCA1/BRCA2 Testing”) and the
USAMRMC Office of Research Protections (Protocol
#A-12074). Written informed consent was obtained from
all participants on Institutional Review Board-approved
consent documents.
Study population
We recruited participants from the Lombardi Compre-
hensive Cancer Center (LCCC) familial cancer registry
(FCR). All participants had received clinical genetic coun-
seling and testing at LCCC, were at least 3 years post-
disclosure of BRCA1/2 test results and had participated in
one of four previous studies: two observational studies of
the short-term outcomes of genetic counseling and testing
[5,24,25] and two post-test intervention trials in BRCA1/2
carriers, one of a psychosocial telephone counseling inter-
vention [26] and one of a computer-based decision aid de-
signed to assist BRCA1/2 carriers in making decisions
about managing their breast cancer risk [27]. All partici-
pants completed a baseline interview prior to pre-test
genetic counseling, from which data are included in the
present study. The individuals randomized to receive in-
terventions did not differ significantly on any of the out-
comes addressed in the analyses in this study.
The present report is limited to BRCA1/2 mutation
carriers. Of 206 potentially eligible BRCA1/2 carriers
who were active in the FCR, we had incorrect contact
information for 9. Of the remaining 197 eligible women,
38 (19.2%) declined participation and 15 (7.6%) could
not be reached after repeated attempts. Our final sample
(N = 144) represents 73.1% of those who were eligible
and for whom we had correct contact information. Par-
ticipants differed from eligible non-participants on three
sociodemographic variables. Participants were more likely
to be White (p = .03), Jewish (p < .001) and college gradu-
ates (p = .003). Participants and decliners did not differ on
any psychosocial or personal/family history variables.
Procedures
We mailed eligible participants study packets containing
a study invitation, Institutional Review Board approved
consent documents, a printed version of the survey, a
stamped return-addressed card to decline participation,
Hooker et al. Hereditary Cancer in Clinical Practice 2014, 12:9 Page 3 of 8
http://www.hccpjournal.com/content/12/1/9and a telephone number to call should they wish to pro-
vide their answers by phone, or decline by phone.
Measures
Control and predictor variables
Sociodemographics
We measured age, race/ethnicity, education, marital sta-
tus, employment status and religion.
Time since receipt of genetic test result
We calculated the time elapsed between the date that
participants received their BRCA1/2 result and the date
they completed the current survey.
Personal and family cancer history
We assessed participants’ personal history of breast and
gynecologic cancer and time since diagnosis. For logistic
regressions, we divided the time since diagnosis variable
into 3 groups: unaffected women, those diagnosed less
than 10 years ago and those diagnosed more than 10 years
ago. We also assessed the number of first- and second-
degree relatives with breast and/or ovarian cancer.
Pre-counseling anxiety
Our measure of baseline anxiety is a composite of two
anxiety measures we used in previous studies. Twenty-
three participants completed the 20-item State Anxiety
subscale of the State Trait Anxiety Inventory (STAI) [28]
and 121 participants completed the anxiety subscale of
the Brief Symptom Inventory (BSI) [29]. As in previous
reports [4,22], we used each participant’s z-score on
the measure they completed as their measure of pre-
counseling anxiety. Both measures are reliable (Cronbach’s
alpha = 0.85 (STAI) and 0.91 (BSI)).
Risk-reducing surgery
Using face-valid interview questions previously described
[4], we assessed receipt of risk-reducing mastectomy
(RRM ever), oophorectomy (RRO ever), time elapsed
since each surgery, and the timing of surgery relative to
genetic testing (pre-testing, post-testing). Women who
had mastectomy or oophorectomy for reasons other than
prevention (e.g. bilateral breast cancer or ovarian cysts)
were excluded from analyses applying these variables.
Outcome variables
Satisfaction with management and genetic testing decisions
All participants completed modified versions of the reli-
able and valid Satisfaction with Decision Making (SWD)
scale [30]. We modified the SWD for the present study
by eliminating a single item, which was phrased “I ex-
pect to successfully carry out (or continue to carry out)
the decision I made”. We deleted this item because
genetic testing, RRO and RRM are one-time decisions.Thus, this item was not applicable to those who had
already obtained either surgery. Previous research has
successfully employed modified versions of this scale
[31]. Participants completed the 5-item modified SWD
scale for satisfaction with genetic testing (alpha = 0.92)
and for satisfaction with management decisions (alpha =
0.94). However, since scores on the SWD were highly
skewed for both outcomes, we dichotomized the scale
dividing those who were “very satisfied” across all items
from those who were less than “very satisfied” on one or
more items.
Quality of life
We assessed quality of life among the affected women in
our sample (N = 97) using the 36-item FACT-B (Func-
tional Assessment of Cancer Therapy- Breast) designed
for use in breast cancer patients (alpha 0.89) [32].
Statistical analysis
We characterized the sample in terms of sociodemo-
graphics, personal history of cancer, cancer treatment and
prevention decisions, anxiety prior to genetic testing and
time since genetic testing. We used chi-square and t-tests
(with Satterthwaite’s approximation for unequal variances
when appropriate) to identify bivariate predictors of satis-
faction with management decisions, satisfaction with gen-
etic testing and, among women with a history of cancer,
quality of life. Next, we used logistic (for satisfaction with
management decisions and satisfaction with the genetic
testing decision) and linear regression (for quality of life)
with hierarchical variable entry in which we included all
main effect variables with p < 0.10 bivariate associations
with the outcome of interest on the first step. Because
quality of life had multiple independent predictors, we
conducted follow-up testing for interactions between the
main effects by entering the interaction term on the sec-
ond step of the linear regression model. For models of sat-
isfaction with management decisions, we excluded women
who had bilateral mastectomies or oophorectomies for
reasons other than prevention. For all models, when test-
ing variables with significant colinearity (e.g. RRM ever,
RRM before genetic testing and time since RRM; RRM be-
fore genetic counseling and time since RRM) we included
only the variable with the stronger bivariate association.
Results
Sample characteristics
As displayed in Table 1, 90 of the 144 (62.5%) BRCA1/2
mutation carriers in this sample had a prior diagnosis of
breast cancer, five had been diagnosed with ovarian cancer,
one had both breast and ovarian cancer and one had breast
and uterine cancer. On average it had been a mean of 5.2
(SD = 1.2) years since genetic testing. Among affected
women, it had been a mean of 10.9 (SD = 7.9) years since
Table 1 Characteristics of the study sample
Cancer history
Breast cancera, N (%) 90 (62.5)
Ovarian cancer, N (%) 5 (3.5)
Both breast and ovarian, N (%) 1 (0.7)
Both breast and endometrial, N (%) 1 (0.7)
Unaffected, N (%) 47 (32.6)
Time since cancer diagnosis, mean (SD) 10.9 (7.9)
Years since testing, mean (SD) 5.2 (1.2)
Age at F/U, mean (SD) 49.6 y (10.0)
Range 32y-76y
College degree or higher, N (%) 139 (96.5)
Jewish, N (%) 48 (33.3)
White, N (%) 135 (93.8)
Married, N (%) 111 (77.1)
Relatives with cancer, mean (SD)
Breast cancer 2.3 (1.2)
Ovarian cancer 0.5 (0.7)
Breast or ovarian cancer 2.8 (1.5)
Oophorectomy
Risk reducing oophorectomyb N (%) 94 (65.2)
Prior to genetic testing, N (%) 29 (20.1)
After genetic testing, N (%) 65 (45.1)
For treatment of ovarian cancer, N (%) 6 (4.2)
Otherc, N (%) 10 (6.9)
Ovaries intact, N (%) 34 (23.6)
Years since risk reducing oophorectomy, mean (SD) 5.49 (4.18)
Mastectomy
Risk reducing mastectomyd,e, N (%) 64 (44.4)
Prior to genetic testing, N (%) 24 (16.6)
After genetic testing, N (%) 40 (27.8)
Bilateral for treatment, N (%) 13 (9.0)
Unilateral for treatment, N (%) 12 (8.3)
Both breasts intact, N (%) 55 (38.2)
Years since risk reducing mastectomy, mean (SD) 6.35 (6.3)
Satisfaction with management decisions, mean (SD) 23.4 (2.87)
Very satisfied with management decisions, % (number) 65.3% (94/144)
Satisfaction with genetic testing decision, mean (SD) 23.6 (2.56)
Very satisfied with genetic testing decisions, % (number) 66.0% (93/141)
Quality of life, FACT-B for affected women, mean (SD) 117.0 (19.0)
Quality of life, SF-12 for unaffected women, mean (SD) 100.8 (14.0)
a4 women with breast cancer were still undergoing chemotherapy b27/47
(57%) unaffected women, 67/90 (74%) women with breast cancer c(ovarian
cysts-7, endometrial ca-2, menstrual discomfort-1) dIncludes both women who
had bilateral prophylactic mastectomy and women who had contralateral
prophylactic mastectomy e17/47 (36%) unaffected women, 47/97 (48%)
women with any cancer history.
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(94%), college educated (96%), and married (77%). The
mean age of participants at long-term follow up was
49.6 (SD 10.0), and they had a mean of 2.8 first or
second-degree relatives with breast or ovarian cancer.
As described in our previous report [4,22], the major-
ity of participants had undergone RRO and almost half
had obtained a RRM at the long term follow up.
Satisfaction and quality of life
Participants reported extremely high satisfaction with
their decision to undergo BRCA1/2 testing and with their
management decisions following receipt of a positive test
result. Over 90% of participants scored a 20 or higher (out
of 25) on both satisfaction scales and over 60% of partici-
pants scored a perfect 25 on both scales.
In bivariate analyses of satisfaction with the genetic test-
ing decision (Table 2), high satisfaction, or being “very sat-
isfied” across all items on the SWD scale, was associated
with: ever having RRM (Χ2 (1, N = 126) = 12.5, p < 0.001),
having had RRM before testing (Χ2 (1, N = 126) 16.04,
p < 0.001), and a shorter time since cancer diagnosis
(r(94) = −0.26, p < 0.05).
High satisfaction with management decisions, also
assessed as scoring a “very satisfied” across all items on
the SWD scale, was associated with: having ever received
an RRM (Χ2 (1, N = 129) = 6.44, p = 0.01) and having ever
received an RRO (Χ2(1, N = 125) = 4.87, p = 0.03). Timing
of RRM and RRO was also associated with satisfaction.
Women who underwent RRM prior to testing were more
likely to report high satisfaction with their management
decisions (Χ2(1, N = 129) = 8.50, p = 0.01) and women
who had RRO prior to testing were also more likely to re-
port high satisfaction (Χ2(1, N = 125) = 6.89, p = 0.03).
Notably, having had a diagnosis of cancer was not signifi-
cantly associated with satisfaction with management deci-
sions or with genetic testing satisfaction.
In terms of quality of life among women with a history
of cancer, greater time since RRM (among affected women
who had RRM) was associated with higher quality of life
(r(48) = 0.32, p = 0.03) and high pretest anxiety was associ-
ated with lower quality of life (r(96) = −0.31, p = .002). Al-
though ever having received RRM or RRO was not
associated with quality of life, timing of RRM was signifi-
cantly associated. Women who underwent RRM prior to
testing reported significantly higher quality of life at
follow-up compared to those who had never undergone
RRM (t(68) = −1.98, p = .05) and those who underwent
RRM after testing (Satterthwaite t(39.8) = 2.11, p = 0.04).
Multivariate models of satisfaction and quality of life
Satisfaction with genetic testing decision
To identify independent predictors of high satisfaction with
the genetic testing decision, we conducted a multiple
Table 2 Bivariate predictors of satisfaction and quality of life






Percent (N) Percent (N) SD Mean (N) SD
Affected status
Unaffected 62% (29) 57% (27) N/A
Prev. cancer diagnosis 67% (65) 70% (66) 116.98 (96) 18.99
Oophorectomy
Ovaries intact 53% (18)* 58% (19) 123.64 (17) 2.83
Risk Reducing Oophorectomy (RRO) 74% (91) 72% (64) 117.67 (64) 2.28
Mastectomy
≥1 at risk breast 55% (36)* 55% (35)** 119.46 (35) 15.11
Risk Reducing Mastectomy (RRM) 77% (49) 84% (52) 118.99 (48) 17.22
Timing of RRM
Pre-testing 88% (21) 1.50* 88% (21)** 124.28 (22) 11.04*a
Post-testing 70% (28) 2.77 82% (31) 114.52 (26) 20.24
Never 55% (36) 2.89 55% (35) 114.98 (48) 20.57
Timing of RRO
Pre 85% (21) 0.88* 69% (18) 116.37 (17) 22.11
Post 69% (45) 2.51 73% (46) 118.15 (47) 16.81
Never 53%(18) 3.47 58% (19) 123.64 (17) 11.68
Continuous variables r r r
Age 0.03 −0.06 −0.01
Time since testing −0.08 −0.05 0.01
Time since diagnosis −0.16 −0.260* <0.01
Time since mastectomy 0.24^ 0.11 0.322*
1st degree relatives w/ breast or ovarian cancer −0.04 −0.05 0.01
Pretest anxiety −0.03 0.08 −0.313**
^p < 0.10 *p < 0.05 **p ≤ 0.001, acompared to women without this prophylactic surgery.
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variate association with genetic testing satisfaction at a sig-
nificance level of p < 0.10 (RRM Ever, RRM before testing
and time since diagnosis). Because RRM ever and RRM be-
fore testing were highly correlated, we included only RRM
ever in the multivariate model due to its stronger bivariate
association. In order to include unaffected women in the
model, we created a dummy coded variable for time since
diagnosis in which unaffected women were the referent
generating comparisons with women diagnosed less than
10 years ago and with women diagnosed more than 10 years
ago. Neither the omnibus time since diagnosis variable
(p = 0.31) nor the constituent comparisons (Table 3) were
significant in the multivariate model. Ever having received
RRM was the only independent predictor of high satisfac-
tion with genetic testing (OR = 4.3, 95% CI: 1.9-9.9).
Satisfaction with management decision
We used the same approach to identify independent pre-
dictors of high satisfaction with management decision.As in the previous model, candidate variables were over-
lapping (e.g., RRO ever and RRO before genetic testing;
RRM ever and RRM before genetic testing and Time
Since Mastectomy). In each case we chose the variable
with the stronger bivariate association with satisfaction.
Given that our questions were anchored on management
of ongoing cancer risk vs. decisions about cancer treat-
ment, and the lack of significant association between
cancer history and satisfaction, we included both un-
affected women and women with a history of cancer in
our model. Thus, our multivariate model included RRO
ever and RRM ever. As displayed in Table 3, both receipt
of RRO (OR = 2.4, 95% CI: 1.0-5.8) and RRM (OR = 2.4,
95% CI: 1.0-5.5) independently predicted high satisfac-
tion with management decisions.
Quality of life
We used linear regression to identify independent predic-
tors of long-term quality of life among women with a per-
sonal history of cancer (n = 97). As above, we included
Table 3 Multivariate predictors of satisfaction and quality
of life
Variable OR 95% CI p
Satisfaction with genetic
testing decision
Step 1 4.3 1.9-9.9 0.001
RRM
Step 2
Time since diagnosis 0.31
Unaffected (Referent) 1.0 – –
Less than 10 years since
diagnosis
2.0 0.8-5.2 0.16





RRO 2.4 1.0-5.5 0.04
RRM 2.4 1.0-5.8 0.05
Quality of life (FACT-B)
Variable Step 1 β Total R2 ΔR2 df Step 2 β
Step 1 0.16***
Baseline anxiety −0.34*** −0.49***
RRM before testing 0.24* 0.21*
Step 2 0.20*** 0.04* 3,92
Anxiety X RRM before
testing
0.26*
*p < 0.05 , **p < 0.01, ***p < 0.001.
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of life: baseline anxiety and RRM prior to testing, exclud-
ing time since mastectomy because of its overlap with
RRM prior to testing. Higher baseline anxiety (β = −0.34,
p < 0.001) independently predicted poorer long-term qual-
ity of life and RRM prior to genetic testing (β = −0.24,
p = 0.01) independently predicted better long-term quality
of life (Table 3). We also identified a significant interaction
between RRM prior to testing and anxiety (β = 0.26,
p = 0.03). Stratified analyses indicated that, among women
who had RRM prior to testing, baseline anxiety did not
predict quality of life (r = −0.14, p = 0.55) but among
women who had not had an RRM prior to testing, base-
line anxiety predicted poorer quality of life (r = −0.42,
p <0.001).
Discussion
This prospective study provides new insights into long-
term satisfaction and quality of life in a U.S. cohort of
BRCA1/2 mutation carriers. Consistent with previous
studies [11-13,17,21,33-35], satisfaction with both the de-
cision to have genetic testing and with specific manage-
ment decisions was extremely high. Overall, more than
60% of the sample reported perfect satisfaction with boththe decision to undergo genetic testing and their manage-
ment decisions following the receipt of genetic testing re-
sults. Given the increasing use of genetic testing, these
data should reassure clinicians and patients regarding the
long-term impact of genetic testing and subsequent med-
ical decision-making.
Although overall satisfaction was extremely high, we
did find that women who opted for RRO or RRM were
significantly more satisfied with their management deci-
sions than women who had not had these surgeries. This
is among the first studies to examine RRO and RRM
decisions concurrently within the same sample. These
analyses add to the limited evidence suggesting that
long-term satisfaction is higher among women who opt
for these risk reduction surgeries compared to those
who do not [17].
Longitudinal studies such as this one provide import-
ant insight into the potential impact of cancer risk as-
sessment and risk reduction over time. Our finding that,
among affected women, time since surgery and having
had RRM before testing are both associated with higher
quality of life supports the idea of a long-term benefit
that may increase over time. Though we were not pow-
ered to detect an effect of time since surgery in our
multivariate model of quality of life, the significant effect
of RRM prior to testing may be due to the fact that these
women also had a greater time since surgery. Women
who had an RRM more recently may still be burdened
by problems with reconstruction and recovery. Alterna-
tively, it may be that the decision to receive risk redu-
cing surgery prior to testing reflects an especially strong
preference for risk reducing surgery; a preference subse-
quently validated by the receipt of a positive test result.
In contrast, women who did not obtain risk reducing
surgery or opted for such surgery after receiving a posi-
tive test result may have had more ambivalence about
the decision, leading to poorer long-term quality of life.
Interestingly, having had an RRM before testing modi-
fied the relationship between baseline anxiety and subse-
quent quality of life. Baseline anxiety did not predict
quality of life among women who had an RRM prior to
testing but predicted poorer quality of life for those who
had not had an RRM prior to genetic testing. This finding
could reflect a response shift among women who had a
RRM prior to testing. Response shift refers to a recalibra-
tion, reprioritization or reconceptualization of quality of
life over time following an impactful event [36]. Perhaps
women who had an RRM prior to testing have had more
time living with the impact of their surgery and as a result
are more likely to exhibit response shift. Thus, their anx-
iety at the start of the study may be less relevant to their
current recalibrated quality of life. Women who had not
obtained an RRM or who obtained one more recently
would be less likely to have exhibited a response shift.
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had an RRM at the time of the initial assessment, self-
reported anxiety may not have been strongly influenced
by concerns about their risk (which had already been
greatly reduced due to their RRM). Thus, the more gen-
eral anxiety they reported at that time would not be
expected to prospectively predict their quality of life. In
contrast, the anxiety among women who had not had
RRM may have more strongly reflected their concerns
about risk. Their current quality of life may reflect the
same anxiety associated with their ongoing burden of liv-
ing at risk.
The findings reported in this study should be inter-
preted in the context of its limitations. First, the study
sample is comprised exclusively of clinical research par-
ticipants seen at a single institution. Consistent with
other studies conducted at large cancer genetics referral
centers, study participants were in general, highly edu-
cated with limited racial diversity. Second, we drew from
data collected from participants prior to genetic testing
(baseline) and at long-term follow up and propose that
difference in time between reference points (testing, sur-
gery, diagnosis) reflect progress of our outcomes over
time. It is also possible that changes not measured or
controlled for in the intervening time periods (e.g. in the
clinical care and follow up of study participants) could
confound the interaction effect between time since
testing and satisfaction with management decisions. We
modified the Satisfaction with Decision scale for this
study, to make it more appropriate for the risk manage-
ment decisions addressed in this study. Additionally,
there may be other differences in variables not assessed
in this study between the group of women who under-
went RRM and those who did not that might contribute
to the differences in outcomes between these groups.
Though our outcomes did not differ with regard to
women’s cancer history, and the focus of this paper is on
risk management, rather than disease management, we
were underpowered to do subgroup analyses of affected
and unaffected women, and cannot rule out cancer treat-
ment variables as potential confounders. Finally, as test-
ing has become more routine, there are likely to be
fewer women who opt for risk reducing surgery prior to
genetic testing – making our results regarding timing of
surgery less relevant to the current clinical setting.
Conclusions
This study is the largest prospective report of long-term
outcomes related to surgical decision making in affected
and unaffected BRCA1/2 carriers. We provide evidence
to support long-term impacts of the decision to undergo
mastectomy and oophorectomy, and the lasting effects
these decisions have as time increases. It is clear, from
this study and others, that receiving a positive test resultis not an isolated stressor, and that there are many on-
going stressors and decisions to be faced over time. As
such, long-term outcomes reflect the combined impact
of these multifaceted experiences. Indeed, in our previ-
ous study from this population, RRM and RRO were
associated with decreased perceived risk for breast and
ovarian cancer [4]. Furthermore, both were associated
decreased distress related to the test result [22]. Though
these results are consistent with our findings, this study
expands insight into the range of outcomes, positive and
negative, experienced by women following testing. These
data can inform decision support provided to women as
they continue to make their decisions over time, and
also the development of targeted interventions to help
women reach decisions that are most satisfying to them.
It is critical that we recognize that living at increased
risk for cancer is not a single event or stressor, and that
there may be utility in continued support over time for
individuals at significantly increased risk. Additionally,
these data can provide some reassurance for women
undergoing surgery that most women are satisfied with
their decision and that their satisfaction and possibly
their overall quality of life seem to increase over time.
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